For patients without established atherosclerotic CV disease (ASCVD) or chronic kidney disease (CKD) and for whom there is a compelling need to minimize weight gain or promote weight loss, the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) guidelines recommend GLP-1RA and sodium-glucose co-transporter-2 inhibitor (SGLT2i) drugs as the preferred second-line treatment option for patients with inadequate glycemic control despite use of metformin [1, 9]
Melatonin, light research protocol, and jet lag [PMID: 11552110] Laboratory literature summary: Melatonin, light research protocol, and jet lag
Havent attained lasting results through dieting and exercising alone
In another Phase 2 trial published in the journal The Lancet in August 2023, patients taking the pill had an average 2.1% reduction in their A1C, a measure of long-term blood sugar, after 26 weeks
e.g., liraglutide) suppress ferroptosis by attenuating oxidative stress and iron overload, thereby preserving cognitive function in experimental models of diabetes